Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial
Objectives: To assess the efficacy and safety of low-dose naltrexone (LDN) for reducing fatigue severity at 16 weeks in persons with post-COVID fatigue syn
Objectives: To assess the efficacy and safety of low-dose naltrexone (LDN) for reducing fatigue severity at 16 weeks in persons with post-COVID fatigue syn